Medications That Deplete Magnesium
Diuretics—particularly loop diuretics (furosemide, bumetanide, torsemide) and thiazide diuretics (chlorothiazide, hydrochlorothiazide)—are the most clinically significant medications causing magnesium depletion, predisposing patients to serious cardiac arrhythmias especially when combined with digitalis therapy. 1, 2, 3
Primary Magnesium-Depleting Medications
Loop and Thiazide Diuretics (Highest Clinical Significance)
Loop diuretics (furosemide, bumetanide, torsemide) and thiazide diuretics (chlorothiazide, hydrochlorothiazide, metolazone) cause depletion of both potassium and magnesium through enhanced delivery of sodium to distal renal tubules and exchange of sodium for other cations 1, 4
Risk is markedly enhanced when two diuretics are used in combination (e.g., furosemide plus metolazone for sequential nephron blockade), which significantly increases electrolyte depletion 1, 3
The electrolyte loss process is potentiated by activation of the renin-angiotensin-aldosterone system 3, 1
Chlorthalidone carries higher potency and greater risk for hypomagnesemia compared to hydrochlorothiazide, with dose-dependent reductions in serum potassium and magnesium 5
Chemotherapeutic Agents (Significant)
Cisplatin is classified as inducing "significant" hypomagnesemia, warranting routine magnesium monitoring, preventive treatment consideration, and treatment initiation with or without overt clinical manifestations 6, 7, 8
Carboplatin belongs to the "potentially significant" category, requiring magnesium monitoring when clinical manifestations are present, persistent electrolyte abnormalities exist, or other precipitating factors coexist 6
Cetuximab (monoclonal antibody) has been linked to hypomagnesemia through effects on gut and kidney magnesium transporters 7
Antimicrobial Agents (Potentially Significant)
Aminoglycosides (amikacin, gentamicin, tobramycin) are classified as "potentially significant" for magnesium depletion, requiring monitoring when symptoms appear, persistent hypocalcemia/hypokalemia exists, or multiple hypomagnesemic drugs are used 6, 7, 8, 9
Amphotericin B induces "significant" hypomagnesemia requiring routine monitoring and preventive treatment 6, 7, 8
Pentamidine and foscarnet cause renal magnesium wasting 6, 9
Immunosuppressants (Significant to Potentially Significant)
- Calcineurin inhibitors (ciclosporin, tacrolimus) cause magnesium depletion, with ciclosporin classified as "significant" and tacrolimus as "potentially significant" 6, 7
Proton Pump Inhibitors (Emerging Concern)
- Proton pump inhibitors have been increasingly recognized as causing hypomagnesemia through effects on intestinal magnesium absorption 7, 10
Clinical Consequences of Magnesium Depletion
Predisposes to serious cardiac arrhythmias, particularly in the presence of digitalis therapy, as magnesium is essential for stabilizing excitable membranes and regulating sodium, potassium, and calcium movement across cells 1, 2, 11
Refractory hypokalemia and hypocalcemia can be caused by concomitant hypomagnesemia and require magnesium therapy for correction 9
Neuromuscular irritability, cardiac arrhythmias, and increased sensitivity to digoxin are common clinical presentations 9
Hypomagnesemia is associated with polymorphic ventricular tachycardia, including torsades de pointes 11
Management Approach
Monitoring Strategy
For "significant" medications (cisplatin, amphotericin B, ciclosporin): Routine magnesium monitoring is warranted, preventive treatment should be considered, and treatment should be initiated with or without overt clinical manifestations 6
For "potentially significant" medications (aminoglycosides, pentamidine, tacrolimus, carboplatin): Monitor when clinical manifestations appear, persistent hypokalemia/hypocalcemia/alkalosis exists, other precipitating factors coexist, or treatment involves multiple hypomagnesemic drugs 6
For diuretics: Concomitant administration of ACE inhibitors alone or with potassium-retaining agents (spironolactone) can prevent electrolyte depletion in most heart failure patients taking loop diuretics 1, 3, 1
Treatment Considerations
Potassium deficits can be corrected by short-term potassium supplements or, if severe, by addition of magnesium supplements 1, 4
For cardiac arrest with suspected hypomagnesemia causing torsades de pointes: IV magnesium 1-2 g MgSO₄ bolus IV push is recommended 11
Loop diuretics can lead to both potassium and magnesium depletion requiring supplementation 12
Common Pitfalls
Serum magnesium can be normal despite intracellular magnesium depletion; a low serum level usually indicates significant deficiency 9
Furosemide and hydrochlorothiazide have "questionable" hypomagnesemic effects according to some classifications, with routine monitoring not required, though ACC/AHA guidelines clearly identify them as causing clinically significant depletion [6 vs 1,3]
When ACE inhibitors and potassium-retaining agents are prescribed with diuretics, long-term oral potassium supplementation frequently is not needed and may be deleterious 1
Drug-magnesium interactions occur because medications and magnesium use the same transport and metabolism pathways for intestinal absorption, metabolism, and elimination 10